Elena Viboch is an investor at SoftBank Investment Advisers (SBIA) where she focuses on investing in technology that impacts human health. Prior to joining SBIA, Elena held corporate development and operations leadership roles at NanoString, Carmot Therapeutics and FLX Bio. She previously managed a public biotechnology portfolio as an investor at Kearny Venture Partners, and started her career in pharmaceutical strategy consulting at Putnam Associates. Elena serves on the board of directors for Karius and as the board observer for Collective Health and Zymergen. She holds an MBA from Harvard Business School where she graduated with highest honors as a Baker Scholar, an MS in Biotechnology from Johns Hopkins University and a BA in Economics with honors from Swarthmore College.